Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug - STAT
STAT Plus: Pharma’s drug spending deflection By Bob Herman Biotech Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug Capricor had previously said its drug, called deramiocel, hit its targets in a Phase 3 study Manage alerts for this article Email this article Share this article Sarah Silbiger/Getty Images By Jason Mast Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.